The short version of IGF-1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-05. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The Health Care Financing Administration (HCFA) was a proponent of the exam noting that it should "significantly increase the pool of personnel qualified for technologist positions in independent labs." Following the exam's discontinuation in 1987, in 1992 HCFA urged the reinstatement of the exam to address the shortage of properly credentialed laboratory personnel. American Association of Bioanalysts (AAB) and the International Society for Clinical Laboratory Technology (ISCLT) supported its reinstatement, while ASCP opposed it. Those who passed the exam were given the designatory letters: CLT (HEW) and later CLT (HHS) for Clinical Laboratory Technologist. HEW certified techs were paid less than the degree-bearing MT ASCP certified techs for the same work. Results of the HEW/HHS exam can be obtained via the HHS System of Records Notices (SORNs) SORN 09–20–0157.
EDC couples primary amines, and other nucleophiles, to carboxylic acids by creating an activated ester leaving group. First, the carbonyl of the acid attacks the carbodiimide of EDC, and there is a subsequent proton transfer. The primary amine then attacks the carbonyl carbon of the acid which forms a tetrahedral intermediate before collapsing and discharging the urea byproduct. The desired amide is obtained.
Legal opium production is allowed under the United Nations Single Convention on Narcotic Drugs and other international drug treaties, subject to strict supervision by the law enforcement agencies of individual countries. The leading legal production method is the Robertson-Gregory process, whereby the entire poppy, excluding roots and leaves, is mashed and stewed in dilute acid solutions. The alkaloids are then recovered via acid-base extraction and purified. The exact date of its discovery is unknown, but it was described by Wurtz in his Dictionnaire de chimie pure et appliquée published in 1868. Legal opium production in India is much more traditional. As of 2008, opium was collected by farmers who were licensed to grow 0.1 hectares (0.25 acres) of opium poppies, who to maintain their licences needed to sell 56 kilograms of unadulterated raw opium paste. The price of opium paste is fixed by the government according to the quality and quantity tendered. The average is around 1500 rupees (US$29) per kilogram. Some additional money is made by drying the poppy heads and collecting poppy seeds, and a small fraction of opium beyond the quota is sometimes consumed locally or diverted to the black market. The opium paste is dried and processed into government opium and alkaloid factories before it is packed into cases of 60 kilograms for export. Purification of chemical constituents is done in India for domestic production, but typically done abroad by foreign importers.
== History == Phase III trials evaluated the efficacy of luspatercept for the treatment of anemia in the hematological disorders beta thalassemia and myelodysplastic syndromes. It was developed by Acceleron Pharma in collaboration with Celgene. The U.S. Food and Drug Administration (FDA) granted approval for luspatercept–aamt in November 2019, for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. Luspatercept was approved for medical use in the European Union in June 2020. The U.S. Food and Drug Administration (FDA) awarded orphan drug status in 2013, and fast track designation in 2015.
1-Aminocyclopropane-1-carboxylic acid (ACC) is a disubstituted cyclic α-amino acid in which a cyclopropane ring is fused to the Cα atom of the amino acid. It is a white solid. Many cyclopropane-substituted amino acids are known, but this one occurs naturally in various fruits. Like glycine, but unlike most α-amino acids, ACC is not chiral.
Sources: en.wikipedia.org
363 people were arrested by the end of the day, primarily for what the police called "minor crimes", but Trevor Manuel of the UDF warned that the house searches were pointless: "the authorities are looking for something they cannot find under beds or wardrobes. The anger of the people over rentals and lack of participation in government does not hide in those places".
=== OSMI === OSMI-1 was first identified from high-throughput screening using fluorescence polarization. Further optimization led to the development of OSMI-2, OSMI-3, and OSMI-4, which bind OGT with low-nanomolar affinity. X-ray crystallography showed that the quinolinone-6-sulfonamide scaffold of OSMI compounds act as a uridine mimetic. OSMI-2, OSMI-3, and OSMI-4 have negatively charged carboxylate groups; esterification renders these inhibitors cell-permeable.
Myeloproliferative disease (primarily essential thrombocythemia and polycythemia vera). It has been found to be superior to anagrelide for the control of ET. Sickle-cell disease (increases production of fetal hemoglobin that then interferes with the hemoglobin polymerisation as well as by reducing white blood cells that contribute to the general inflammatory state in sickle cell patients.) Second line treatment for psoriasis (slows down the rapid division of skin cells) Systemic mastocytosis with associated hematological neoplasm(SM-AHN) (The utility in treating SM-AHN with hydroxycarbamide stems from its myelosuppressive activity, it does not however exhibit any selective anti-mast cell activity) Chronic myelogenous leukemia (largely replaced by imatinib, but still in use for its cost-effectiveness)
Seven people were killed in a Russian attack on the offices of Ukraine's largest printing house, located in Kharkiv. One person was killed in a separate attack in Zaporizhzhia Oblast. Russian-installed authorities in Crimea claimed that two people were killed in a Ukrainian missile attack in Simferopol Raion. The pro-Ukrainian partisan group Atesh claimed that the attack targeted a communications hub in Alushta, while other attacks were reported on a military antenna in Semydviria, Belbek airfield and in Yevpatoria. Ukraine claimed to have shot down a Russian Su-25 jet over the Donbas. Several sources questioned this claim, stating that the footage of the incident appeared to have been taken from a video game. Russia claimed to have shot down a drone over Tatarstan. Officials claimed that one person was killed in a drone strike in Belgorod Oblast. Norway pledged a $190 million military aid package to Ukraine that included support for air defense, naval capabilities, radar, anti-drone systems, and boats. Russia warned the UK that it could strike British targets "on Ukraine's territory and beyond its borders" if weapons it supplied to Ukraine are used against targets on Russian soil. The first group of Ukrainian pilots passed the US F-16 training program at Morris Air National Guard Base in Arizona and will undergo further training in Europe. Putin signed a decree allowing the assets of the United States, its citizens, and its companies to be confiscated and used for compensation for losses incurred by international sanctions.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.